Fujifilm (TSE:4901) is spending big to double the size of its United Kingdom-based vaccine manufacturing facility.
According to a news release, Fujifilm is spending about $532.8 million (£400 million) to expand its Teesside (north-east England) plant making the Novavax COVID-19 vaccine. The expansion includes facilities specializing in antibody treatments and viral gene therapies.
Fujifilm said the facilities are set to open in 2023 or early 2024, with up to 350 highly skilled jobs created in contract manufacturing.
Get the full story at our sister site, Pharmaceutical Processing World.